Wealth Enhancement Advisory Services LLC Sells 4,496 Shares of Xeris Biopharma Holdings, Inc. $XERS

Wealth Enhancement Advisory Services LLC trimmed its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 14.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,758 shares of the company’s stock after selling 4,496 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Xeris Biopharma were worth $127,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Xponance Inc. bought a new stake in Xeris Biopharma during the 1st quarter worth approximately $57,000. FORA Capital LLC bought a new stake in Xeris Biopharma during the 1st quarter worth approximately $60,000. FNY Investment Advisers LLC bought a new stake in Xeris Biopharma during the 1st quarter worth approximately $63,000. Pallas Capital Advisors LLC bought a new stake in Xeris Biopharma during the 1st quarter worth approximately $84,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Xeris Biopharma during the 1st quarter worth approximately $86,000. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Stock Down 2.4%

Xeris Biopharma stock opened at $7.99 on Friday. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.78 and a 12-month high of $8.51. The firm’s fifty day moving average is $7.63 and its 200 day moving average is $5.73. The company has a market capitalization of $1.29 billion, a PE ratio of -38.05 and a beta of 0.39.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analyst estimates of $64.58 million. Sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, Director Marla Persky sold 15,500 shares of the company’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $7.72, for a total transaction of $119,660.00. Following the transaction, the director owned 142,000 shares in the company, valued at approximately $1,096,240. This represents a 9.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Dawn Halkuff sold 42,500 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total transaction of $309,400.00. Following the transaction, the director owned 115,000 shares in the company, valued at approximately $837,200. The trade was a 26.98% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 207,732 shares of company stock worth $1,550,437. Corporate insiders own 6.47% of the company’s stock.

Analyst Ratings Changes

XERS has been the topic of a number of research reports. HC Wainwright initiated coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday. Leerink Partners upped their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a research note on Tuesday, August 19th. Finally, Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.08.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.